Title The different temozolomide effects on tumorigenesis mechanisms of pediatric Glioblastoma PBT24 and SF8628 cell tumor in CAM model and on cells In Vitro /
Authors Damanskienė, Eligija ; Balnytė, Ingrida ; Valančiūtė, Angelija ; Alonso, Marta Maria ; Preikšaitis, Aidanas ; Stakišaitis, Donatas
DOI 10.3390/ijms23042001
Full Text Download
Is Part of International journal of molecular sciences.. Basel : MDPI. 2022, vol. 23, iss. 4, art. no. 2001, p. 652-656.. ISSN 1661-6596. eISSN 1422-0067
Keywords [eng] pediatric glioblastoma ; temozolomide ; NKCC1 ; KCC2 ; EZH2 ; PCNA ; CAM
Abstract [eng] It is necessary to elucidate the individual effects of temozolomide (TMZ) on carcinogenesis and tumor resistance to chemotherapy mechanisms. The study aimed to investigate the TMZ 50 and 100 µM dose effect difference between PBT24 and SF8628 cell line high-grade pediatric glioblastoma (phGBM) xenografts in a chicken chorioallantoic membrane (CAM) model, on PCNA and EZH2 immunohistochemical expression in the tumor and on the expression of NKCC1, KCC2, E-and N-cadherin genes in TMZ-treated and control cell groups in vitro. TMZ at a 100 µg dose reduced the incidence of PBT24 xenograft invasion into the CAM, CAM thickening and the number of blood vessels in the CAM (p < 0.05), but did not affect the SF8628 tumor in the CAM model. The TMZ impact on PBT24 and SF8628 tumor PCNA expression was similarly significantly effective but did not alter EZH2 expression in the studied tumors. The TMZ at 50 µM caused significantly increased RNA expression of the NKCC1 gene in both studied cell types compared with controls (p < 0.05). The expression of the KCC2 gene was increased in PBT24 TMZ-treated cells (p < 0.05), and no TMZ effect was found in SF8628-treated cells. The study supports the suggestion that individual sensitivity to TMZ should be assessed when starting treatment.
Published Basel : MDPI
Type Journal article
Language English
Publication date 2022
CC license CC license description